Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients - Trial NCT06364072
Access comprehensive clinical trial information for NCT06364072 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Cessatech A/S and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cessatech A/S
Timeline & Enrollment
Phase 2/3
Apr 15, 2024
Sep 20, 2024
Primary Outcome
To assess the safety and tolerability,To evaluate the analgesic effect
Summary
The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and
 feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an
 acute care (i.e. emergency) setting. The study is a part of the clinical development plan for
 the development of CT001 nasal spray for treatment of acute pain in children.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364072
Non-Device Trial